Finally, sequential measurement of these AKI biomarkers (e.g., daily, weekly) or other AKI biomarkers (e.g., kidney injury molecule-1, liver fatty acid-binding proteins) may reflect the dynamic aspects of clinical diseases and thus provide superior information on mortality risk. The gene discussed is HAVCR1; the disease is acute kidney injury.